Quantcast
Last updated on April 21, 2014 at 1:20 EDT

Latest Docetaxel Stories

2012-08-07 06:25:58

BOTHELL, Wash., and VANCOUVER, British Columbia, Aug. 7, 2012 /PRNewswire/ -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that it has initiated patient enrollment in its second Phase 3 clinical trial evaluating custirsen in patients with advanced prostate cancer. The AFFINITY trial will evaluate if custirsen when combined with second-line chemotherapy has the potential to improve survival outcomes for prostate cancer patients compared to second-line chemotherapy alone....

2012-07-09 06:28:25

BETHLEHEM, Pa., July 9, 2012 /PRNewswire/ -- Saladax Biomedical, Inc., a privately held company developing and commercializing novel diagnostic assays to achieve the promise of personalized medicine for new and existing therapeutics, announced today the company has achieved CE mark registration for its MyPaclitaxel(TM) and MyDocetaxel(TM) therapeutic dose management (TDM) MyCare(TM) assays, enabling commercialization in the European Union (EU). Saladax's MyCare technology platform...

2012-06-05 02:27:45

--Company to Host Conference Call to Discuss Randomized Phase II Program-- CALGARY, June 5, 2012 /PRNewswire/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC) (NASDAQ:ONCY) announced today that it has entered into an agreement whereby the NCIC Clinical Trials Group (CTG) at Queen's University in Kingston, Ontario, will sponsor and conduct a randomized Phase II study of REOLYSIN(®) in patients with advanced or metastatic non-small cell lung cancer ("NSCLC"). "This agreement...

2012-06-04 02:25:49

Phase 3 Results Show Significant Improvement in Radiographic Progression-Free Survival and a Trend for Increased Overall Survival in Patients Receiving ZYTIGA® Plus Prednisone TORONTO, June 2, 2012 /CNW/ - New data presented this weekend at the 48(th) annual meeting of the American Society of Clinical Oncology (ASCO) showed ZYTIGA® (abiraterone acetate) may prove to be an important new treatment option for metastatic prostate cancer patients prior to receiving chemotherapy....

2012-06-02 10:20:13

SEATTLE, June 2, 2012 /PRNewswire/ - Oncothyreon Inc. (Nasdaq: ONTY) today announced that data from two clinical trials of PX-866, a pan-isoform phosphatidylinositol-3-kinase (PI-3K) inhibitor, were presented today at the American Society of Clinical Oncology (ASCO) meeting in Chicago.  Oncothyreon also provided an update on the status of its ongoing Phase 2 development program for PX-866. Phase 1 Trial of PX-866 in Combination with Docetaxel Data from the Phase 1 portion of...

2012-06-01 18:20:41

CHICAGO, June 2, 2012 /PRNewswire/ -- Results observed from pre-specified interim analyses of the randomized, placebo-controlled Phase 3 study, COU-AA-302, demonstrated that patients with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone acetate (ZYTIGA(®)) plus prednisone showed a statistically significant improvement in radiographic progression-free survival (rPFS) and all secondary endpoints compared to patients treated with placebo plus...

2012-05-29 10:09:41

Added benefit in men with metastatic hormone-refractory prostate cancer for whom docetaxel is no longer an option Cabazitaxel (trade name: Jevtana®) has been approved since March 2011 in men with metastatic prostate cancer who no longer respond to conventional therapy with hormone blockers and have already been pre-treated with the cytostatic drug docetaxel. In an early benefit assessment pursuant to the "Act on the Reform of the Market for Medicinal Products” (AMNOG), the German...

2012-05-18 02:24:27

RARITAN, N.J., May 18, 2012 /PRNewswire/ -- Data related to ZYTIGA® (abiraterone acetate) clinical studies have been selected for presentation at the 48th Annual Meeting of the American Society of Clinical Oncology (ASCO). Additionally, data regarding the investigational compounds ibrutinib and siltuximab also have been accepted for presentation. Additional abstracts were also accepted as publication-only or in the trial in progress category. These studies were sponsored by...

2012-05-03 02:32:03

NEW ORLEANS, May 3, 2012 /PRNewswire-FirstCall/ -- ICU Medical, Inc. (NASDAQ: ICUI) today announced that two studies presented this week at the 37th Annual Congress of the Oncology Nursing Society (ONS) in New Orleans show that the company's ChemoClave(TM) needlefree closed system transfer device (CSTD) protects nurses from accidental exposure to hazardous chemotherapy drugs while increasing nurse satisfaction and perceptions of safety. The ChemoClave system is the world's...

2012-05-01 06:27:42

EAST SETAUKET, N.Y., May 1, 2012 /PRNewswire/ -- John S. Kovach, M.D., Chair, Board of Directors and CEO of Lixte Biotechnology Holdings, Inc. (LIXT.PK), announced the submission of an IND application to the Food and Drug Administration to conduct a Phase I trial of its lead, anti-cancer compound, LB-100. Dr. Kovach said, "We believe that LB-100, a novel anti-cancer compound, prevents cancer cells from defending themselves against standard types of cancer treatments. In...